New in Metastatic Breast Cancer: What Your Patients Need to Know About the TROPiCS-02 Trial

TROPiCS-02 was a phase III trial that enrolled patients with metastatic, or inoperable locally recurrent breast cancer, that was hormone receptor positive and HER2 negative and had progressed following at least one first-line treatment. The trial enrolled just under 550 patients and was designed to determine whether treatment with a novel drug, sacituzumab govitecan (SG), was superior to using the physician’s choice of chemotherapy in this group of patients. The initial results of this trial were positive, showing that patients on SG had a significant, 34% reduction in their overall risk for death or progression of their disease, compared to those who received chemotherapy. A higher proportion of patients on SG were also alive, and free of progression at 6 months, 9 months, and 1 year after starting the trial. In addition, a significantly greater proportion of patients showed a response to SG treatment, as measured by shrinkage of their tumors (21%, versus 14% for patients on chemotherapy). This trial is ongoing, and it is not known yet whether the patients receiving SG survived for a longer period versus those on chemotherapy.

Related Posts

See All